Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

被引：0
作者：
Roy M. Fleischmann
Daniel F. Alvarez
Amy E. Bock
Carol Cronenberger
Ivana Vranic
Wuyan Zhang
Rieke Alten
机构：
[1] Metroplex Clinical Research Center,University of Texas Southwestern Medical Center at Dallas
[2] Pfizer Inc.,Schlosspark
[3] Pfizer Inc.,Klinik
[4] Pfizer,undefined
[5] Pfizer Inc.,undefined
[6] University Medicine Berlin,undefined
来源：
Arthritis Research & Therapy | / 23卷
关键词：
Adalimumab; Adalimumab-afzb; Biosimilar; PF-06410293; Rheumatoid arthritis; Long-term; Switch; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 18 条
  • [1] Weinblatt ME(2006)Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study Ann Rheum Dis. 65 753-759
  • [2] Keystone EC(2020)PF-06410293: an adalimumab biosimilar BioDrugs. 34 695-698
  • [3] Furst DE(2020)Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab Regul Toxicol Pharmacol. 112 104587-undefined
  • [4] Kavanaugh AF(undefined)undefined undefined undefined undefined-undefined
  • [5] Chartash EK(undefined)undefined undefined undefined undefined-undefined
  • [6] Segurado OG(undefined)undefined undefined undefined undefined-undefined
  • [7] Lee A(undefined)undefined undefined undefined undefined-undefined
  • [8] Shirley M(undefined)undefined undefined undefined undefined-undefined
  • [9] Derzi M(undefined)undefined undefined undefined undefined-undefined
  • [10] Shoieb AM(undefined)undefined undefined undefined undefined-undefined
12